Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease.

Llibre-Guerra JJ, Li Y, Schindler SE, Gordon BA, Fagan AM, Morris JC, Benzinger TLS, Hassenstab J, Wang G, Allegri R, Berman SB, Chhatwal J, Farlow MR, Holtzman DM, Jucker M, Levin J, Noble JM, Salloway S, Schofield P, Karch C, Fox NC, Xiong C, Bateman RJ, McDade E.

JAMA Netw Open. 2019 Dec 2;2(12):e1917126. doi: 10.1001/jamanetworkopen.2019.17126.

PMID:
31825500
2.

Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia.

Day GS, Cruchaga C, Wingo T, Schindler SE, Coble D, Morris JC.

JAMA Netw Open. 2019 Oct 2;2(10):e1913491. doi: 10.1001/jamanetworkopen.2019.13491.

3.

Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease.

Bos I, Vos SJB, Schindler SE, Hassenstab J, Xiong C, Grant E, Verhey F, Morris JC, Visser PJ, Fagan AM.

Alzheimers Dement. 2019 Sep;15(9):1149-1159. doi: 10.1016/j.jalz.2019.04.015. Epub 2019 Aug 1.

PMID:
31378575
4.

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.

Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ.

Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1.

PMID:
31371569
5.

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.

Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2019 May;15(5):655-665. doi: 10.1016/j.jalz.2018.12.019. Epub 2019 Mar 4.

PMID:
30846386
6.

ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.

Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, Li QX, Collins SJ, Carlsson C, Asthana S, Masters CL, Johnson S, Morris JC, Albert M, Gross AL.

Neurology. 2019 Apr 2;92(14):e1567-e1579. doi: 10.1212/WNL.0000000000007248. Epub 2019 Mar 6.

PMID:
30842300
7.

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.

Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C.

JAMA Neurol. 2019 Mar 1;76(3):264-273. doi: 10.1001/jamaneurol.2018.4249.

8.

Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC.

Brain. 2018 Nov 1;141(11):3233-3248. doi: 10.1093/brain/awy244.

9.

Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.

Merluzzi AP, Carlsson CM, Johnson SC, Schindler SE, Asthana S, Blennow K, Zetterberg H, Bendlin BB.

Neurology. 2018 Jul 31;91(5):e436-e443. doi: 10.1212/WNL.0000000000005901. Epub 2018 Jun 29.

10.

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.

Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM.

Alzheimers Dement. 2018 Nov;14(11):1460-1469. doi: 10.1016/j.jalz.2018.01.013. Epub 2018 Mar 2.

11.

Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.

Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM.

Alzheimers Dement. 2018 Jan;14(1):62-70. doi: 10.1016/j.jalz.2017.06.2264. Epub 2017 Jul 12. Erratum in: Alzheimers Dement. 2018 Aug;14(8):1100.

12.

Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease.

Schindler SE, Jasielec MS, Weng H, Hassenstab JJ, Grober E, McCue LM, Morris JC, Holtzman DM, Xiong C, Fagan AM.

Neurobiol Aging. 2017 Aug;56:25-32. doi: 10.1016/j.neurobiolaging.2017.04.004. Epub 2017 Apr 14.

13.

Double Monoclonal Immunoassay for Quantifying Human Visinin-Like Protein-1 in CSF.

Crimmins DL, Herries EM, Ohlendorf MF, Brada NA, Garbett NC, Zipfel GJ, Schindler SE, Ladenson JH.

Clin Chem. 2017 Feb;63(2):603-604. doi: 10.1373/clinchem.2016.263236. Epub 2016 Dec 16. No abstract available.

14.

Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

How J, Blattner M, Fowler S, Wang-Gillam A, Schindler SE.

Neurologist. 2016 Nov;21(6):112-117. Review.

PMID:
27801773
15.

CSF sTREM2: marking the tipping point between preclinical AD and dementia?

Schindler SE, Holtzman DM.

EMBO Mol Med. 2016 May 2;8(5):437-8. doi: 10.15252/emmm.201606245. Print 2016 May. No abstract available.

16.

Photo-activatable Cre recombinase regulates gene expression in vivo.

Schindler SE, McCall JG, Yan P, Hyrc KL, Li M, Tucker CL, Lee JM, Bruchas MR, Diamond MI.

Sci Rep. 2015 Sep 9;5:13627. doi: 10.1038/srep13627.

17.

Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD.

Schindler SE, Fagan AM.

Front Neurol. 2015 Jun 29;6:142. doi: 10.3389/fneur.2015.00142. eCollection 2015. Review.

18.

Advances in diagnostic testing for Alzheimer disease.

Schindler SE, McConathy J, Ances BM, Diamond MI.

Mo Med. 2013 Sep-Oct;110(5):401-5. Review.

19.

Alzheimer disease: current concepts & future directions.

Musiek ES, Schindler SE.

Mo Med. 2013 Sep-Oct;110(5):395-400. Review.

Supplemental Content

Loading ...
Support Center